Scholarlink

Purpose <p>The present systematic review investigated the efficacy of intra-articular hyaluronic acid (HA) viscosupplementation for hip osteoarthritis (OA) in patient-reported outcome measures (PROMs) and whether different molecular weights of HA are associated with different outcomes.</p> Methods <p>This study was conducted according to the 2020 PRISMA statement. In January 2025, PubMed, Web of Science, Google Scholar, and Embase were accessed. All the randomised controlled trials (RCTs) evaluating the efficacy of intra-articular HA injections in the hip for OA were included.</p> Results <p>Nine hundred and eighty-two patients (56% women, mean age 62.2 ± 4.0&#xa0;years, mean follow-up 6.4 ± 2.7&#xa0;months, mean BMI 27.5 ± 2.1&#xa0;kg/m<sup>2</sup>) were analysed. Patients receiving high molecular weight (HMW) and low molecular weight (LMW) HA showed significant improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analogue scale (VAS) scores (<i>P</i> &lt; 0.05). No significant differences in VAS or WOMAC were observed among groups at 3–4&#xa0;months of follow-up. However, at 4–6&#xa0;months, the HMW HA group exhibited significantly lower VAS scores compared to the medium molecular weight (MMW) (mean difference, MD − 1.4, 95% CI − 2.1 to − 0.7, <i>P </i>&lt; 0.0001), placebo (MD − 1.6, 95% CI − 2.1 to − 1.1, <i>P</i> &lt; 0.0001), and control (MD − 1.3, 95% CI − 1.8 to − 0.8, <i>P </i>&lt; 0.0001) groups. WOMAC scores at 4–6&#xa0;months demonstrated that both HMW and MMW HA performed better than the control group (<i>P</i> &lt; 0.0001), but no significant difference was observed between HMW and MMW (<i>P</i> = 1.0).</p> Conclusion <p>Intra-articular injections of HA effectively reduce knee OA symptoms. Moreover, HMW HA performs better than MMW HA at a mean of 4–6&#xa0;months of follow-up.</p> Level of evidence <p>Level I, systematic review of RCTs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intra-articular hyaluronic acid injections for hip osteoarthritis: a level I systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月9日

查看全文
  • Filippo Migliorini,
  • Marco Pilone,
  • Manuel Giovanni Mazzoleni,
  • Luise Schäfer,
  • Dragana Katusic,
  • Nicola Maffulli

摘要

Purpose

The present systematic review investigated the efficacy of intra-articular hyaluronic acid (HA) viscosupplementation for hip osteoarthritis (OA) in patient-reported outcome measures (PROMs) and whether different molecular weights of HA are associated with different outcomes.

Methods

This study was conducted according to the 2020 PRISMA statement. In January 2025, PubMed, Web of Science, Google Scholar, and Embase were accessed. All the randomised controlled trials (RCTs) evaluating the efficacy of intra-articular HA injections in the hip for OA were included.

Results

Nine hundred and eighty-two patients (56% women, mean age 62.2 ± 4.0 years, mean follow-up 6.4 ± 2.7 months, mean BMI 27.5 ± 2.1 kg/m2) were analysed. Patients receiving high molecular weight (HMW) and low molecular weight (LMW) HA showed significant improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analogue scale (VAS) scores (P < 0.05). No significant differences in VAS or WOMAC were observed among groups at 3–4 months of follow-up. However, at 4–6 months, the HMW HA group exhibited significantly lower VAS scores compared to the medium molecular weight (MMW) (mean difference, MD − 1.4, 95% CI − 2.1 to − 0.7, P < 0.0001), placebo (MD − 1.6, 95% CI − 2.1 to − 1.1, P < 0.0001), and control (MD − 1.3, 95% CI − 1.8 to − 0.8, P < 0.0001) groups. WOMAC scores at 4–6 months demonstrated that both HMW and MMW HA performed better than the control group (P < 0.0001), but no significant difference was observed between HMW and MMW (P = 1.0).

Conclusion

Intra-articular injections of HA effectively reduce knee OA symptoms. Moreover, HMW HA performs better than MMW HA at a mean of 4–6 months of follow-up.

Level of evidence

Level I, systematic review of RCTs.